Production and radiochemistry of antimony-120m: Efforts toward Auger electron therapy with 119Sb

Thomas I Kostelnik; Aeli P Olson; Aivija Grundmane; Paul A Ellison; Jenasee Mynerich; Shaohuang Chen; Atanaska Marinova; Parmissa Randhawa; Dimitar Karaivanov; Eduardo Aluicio-Sarduy; Todd E Barnhart; Chris Orvig; Caterina F Ramogida; Cornelia Hoehr; Dmitry Filosofov; Jonathan W Engle; Valery Radchenko

doi:10.1016/j.nucmedbio.2023.108352

Production and radiochemistry of antimony-120m: Efforts toward Auger electron therapy with ¹¹⁹Sb

Nucl Med Biol. 2023 Jul-Aug:122-123:108352. doi: 10.1016/j.nucmedbio.2023.108352. Epub 2023 Jun 12.

Authors

Thomas I Kostelnik¹, Aeli P Olson², Aivija Grundmane³, Paul A Ellison², Jenasee Mynerich⁴, Shaohuang Chen³, Atanaska Marinova⁵, Parmissa Randhawa³, Dimitar Karaivanov⁵, Eduardo Aluicio-Sarduy², Todd E Barnhart², Chris Orvig¹, Caterina F Ramogida³, Cornelia Hoehr⁶, Dmitry Filosofov⁵, Jonathan W Engle², Valery Radchenko⁷

Affiliations

¹ Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada.
² Department of Medical Physics, University of Wisconsin-Madison, Madison, WI 53705, United States.
³ Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada.
⁴ Faculty of Science, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4K1, Canada.
⁵ Dzhelepov Laboratory of Nuclear Problems, Joint Institute for Nuclear Research, Dubna 141980, Russian Federation.
⁶ Department of Physics and Astronomy, University of Victoria, Victoria, British Columbia V8W 2Y2, Canada; Department of Computer Science, Mathematics, Physics, and Statistics, University of British Columbia Okanagan, Kelowna, British Columbia V1V 1V7, Canada.
⁷ Department of Chemistry, University of British Columbia, 2036 Main Mall, Vancouver, British Columbia V6T 1Z1, Canada. Electronic address: vradchenko@triumf.ca.

PMID: 37390607
DOI: 10.1016/j.nucmedbio.2023.108352

Abstract

Targeted Meitner-Auger Therapy (TMAT) has potential for personalized treatment thanks to its subcellular dosimetric selectivity, which is distinct from the dosimetry of β^- and α particle emission based Targeted Radionuclide Therapy (TRT). To date, most clinical and preclinical TMAT studies have used commercially available radionuclides. These studies showed promising results despite using radionuclides with theoretically suboptimal photon to electron ratios, decay kinetics, and electron emission spectra. Studies using radionuclides whose decay characteristics are considered more optimal are therefore important for evaluation of the full potential of Meitner-Auger therapy; ¹¹⁹Sb is among the best such candidates. In the present work, we develop radiochemical purification of ¹²⁰Sb from irradiated natural tin targets for TMAT studies with ¹¹⁹Sb.

Keywords: Antimony-119; Liquid-liquid extraction; Natural tin; Proton irradiation; Targeted Meitner-Auger Therapy.

MeSH terms

Antimony* / therapeutic use
Electrons*
Radiochemistry
Radioisotopes / therapeutic use
Radiopharmaceuticals / therapeutic use

Substances

Antimony
Radioisotopes
Radiopharmaceuticals